查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1995169

抗減肥藥市場：依治療方法、藥物類型、給藥途徑、劑型及通路分類－2026-2032年全球市場預測

Anti-Obesity Therapeutics Market by Treatment Type, Drug Type, Route Of Administration, Drug Formulation, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，抗減肥藥市場價值將達到 116.9 億美元，到 2026 年將成長到 126.7 億美元，到 2032 年將達到 212.1 億美元，複合年成長率為 8.87%。

主要市場統計數據
基準年 2025 116.9億美元
預計年份：2026年 126.7億美元
預測年份 2032 212.1億美元
複合年成長率 (%) 8.87%

這是一本權威的指南，旨在為決策者介紹不斷發展的抗減肥藥生態系統，並提出了科學進步、臨床實踐和商業性需求的框架。

全球對抗肥胖的努力正加速發展成為一個至關重要的多學科領域，生物醫學創新、臨床實踐、保險公司決策和患者期望在此交匯融合。近年來，我們見證了新藥療法的湧現、外科和內視鏡介入技術的進步，以及對長期治療效果和安全性的日益關注。在此背景下，相關人員必須應對複雜的法規環境、不斷變化的報銷趨勢以及社會對醫療服務可近性和公平性的日益關注。

科學突破、交付方式創新和護理路徑重組的清晰融合，正在重塑治療可能性和商業策略。

科學、監管和商業性因素的共同作用，已將抗減肥藥的格局從漸進式改進轉變為變革性改變。胜肽類和腸促胰島素生物學的突破性進展正在重新定義治療標靶和臨床預期，從而刺激了對藥物和器械干預措施的新投資。同時，真實世界數據（REWED）和長期臨床計畫越來越重視安全性訊號和衛生經濟學考量，使製造商和支付者能夠更早就對患者和醫療保健系統至關重要的結果達成一致。

分析檢視近期關稅政策如何促進抗肥胖藥物整個產品生命週期中的供應鏈韌性、採購轉移和商業性調整。

美國2025年實施的關稅措施為抗減肥藥供應鏈中的製造商、經銷商和醫療保健提供者帶來了新的考量。雖然關稅政策只是眾多因素之一，但它已對採購、定價策略和分銷物流產生了直接的營運影響。受關稅影響的原料採購企業被迫重新審查與供應商的契約，盡可能擴大國內採購，並模擬關稅對下游貿易流量和合約義務的影響。

基於策略性細分的洞察，揭示治療方法、給藥方法、配方和分銷管道的差異，從而指導開發重點和商業化選擇。

細分市場洞察提供了必要的詳細觀點，以協調臨床開發、商業性實施和患者需求。根據治療類型，市場分為兩大類：「藥物」和「治療方法」。在「藥物」類別下，我們將更詳細地分析安非他酮/納曲酮、Liraglutide、奧利司他、芬特明/托吡酯、Semaglutide和替澤帕肽。在「治療方法」類別下，我們將評估可調式胃束帶術、內視鏡袖狀胃成形術和胃繞道手術。這種雙軸分析突顯了藥物創新和手術干預如何在醫療保健路徑中並存和競爭，以及慢性藥物治療與一次性或間歇性手術干預在決策上的差異。

對監管、支付方和臨床趨勢進行詳細的區域評估，以確定每個主要全球區域不同的打入市場策略。

區域因素持續影響監管路徑、支付方行為、臨床實務規範以及病患用藥途徑，並對產品策略產生重大影響。在美洲，圍繞保險覆蓋範圍和可負擔性的政策辯論與臨床醫生對新藥日益深入的了解交織在一起，這既為藥物的可及性創造了機遇，也帶來了提供可靠療效數據的壓力。在該地區運營的製藥企業必須平衡積極的證據產生、積極的支付方參與以及患者支持能力，以確保藥物的永續推廣。

一份全面的競爭分析報告，揭示了製藥、生物技術和醫療設備公司如何透過證據、夥伴關係和綜合護理解決方案實現差異化。

抗減肥藥的競爭格局呈現出多元化的格局，大型製藥企業，也有高度專業化的生物技術公司，還有專注於醫療設備的公司，它們都致力於將臨床差異化與可擴展的商業化相結合。成熟的生物製藥公司利用其研發專長和全球分銷網路，拓展適應症範圍並進行全生命週期管理；而生物技術公司則往往專注於新穎的作用機制、目標患者群體以及以夥伴關係主導的商業化。

為高階主管提供可操作的、高優先級的行動方案，以協調證據生成、患者支持、供應彈性和夥伴關係，從而實現永續的商業性成功。

為了將科學預期轉化為永續的影響，產業領導者應優先採取以下幾個切實可行的步驟。首先，透過將衛生經濟學終點和可操作的結果納入主要試驗和上市後監測，使臨床開發與支付方的證據需求保持一致。這將縮短獲得保險覆蓋所需的時間，並降低獲得治療的門檻。其次，要認知到真實世界中的治療依從性是長期治療價值的關鍵促進因素，並投資於以患者為中心的支持模式，以解決治療啟動、藥物依從性和耐受性管理等問題。

為了支持結論，我們採用了一種透明的混合方法研究途徑，結合了相關人員訪談、臨床文獻綜述、監管分析和基於情境的整合。

本研究採用混合方法，整合一手與二手研究，以提供嚴謹且多角度的觀點。一手研究包括對臨床機構、保險公司、製藥業和分銷管道等相關人員進行結構化訪談，並輔以對監管指南和公開臨床試驗註冊資訊的詳細審查。二手分析包括同行評審的臨床文獻、最新的安全性資訊和已發布的衛生技術評估決定，確保依證反映療效和真實世界表現。

簡明扼要地整合策略挑戰，強調證據、病人就醫途徑和綜合照護模式是產生長期影響的決定性因素。

總之，抗減肥藥市場已進入成熟階段，其特點是科學取得了顯著進步，人們對藥物安全性和長期療效的期望不斷提高，以及複雜的商業性動態，包括供應鏈和政策方面的考慮。在此環境下取得成功取決於能否提供令人信服的對比證據，開發以患者為中心的支援項目，並調整商業模式以降低定價和採購風險。同時，能夠整合藥物創新、手術方案和數位化支持，從而提供全面且永續的治療路徑的公司，也擁有許多發展機會。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：治療方法分類的抗減肥藥市場

  • 製藥
    • 安非他酮納曲酮
    • Liraglutide
    • 奧利司他
    • 托吡拉芬特明
    • Semaglutide
    • Tirzepatide
  • 治療方法
    • 可調式胃束帶手術
    • 內視鏡袖狀胃切除術
    • 胃繞道手術

第9章：按藥物類型分類的抗減肥藥市場

  • 非處方藥
  • 處方藥

第10章：抗減肥藥市場：依給藥途徑分類

  • 口服
    • 膠囊
    • 藥片
  • 腸外給藥
    • 靜脈
    • 皮下

第11章 以劑型分類的減肥藥市場

  • 液體
  • 半固態製劑
  • 固態劑型

第12章：抗減肥藥市場：依通路分類

  • 醫院、診所、藥房
  • 網路藥房
  • 零售藥房

第13章：抗減肥藥市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：抗減肥藥市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：抗減肥藥市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國抗減肥藥市場

第17章：中國抗減肥藥市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Alizyme PLC
  • Amgen Inc.
  • Arena Pharmaceuticals Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Currax Pharmaceuticals LLC
  • Eisai Co. Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • FlaxoSithKline plc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • Nalpropion Pharmaceuticals Inc.
  • Norgine BV
  • Novartis AG
  • Novo Nordisk A/S
  • Orexigen Therapeutics Inc.
  • Pfizer Inc.
  • Rhythm Pharmaceuticals, Inc.
  • Sanofi SA
  • SHIONOGI & Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Vivus Inc.
  • Zydus Lifesciences Limited
Product Code: MRR-EC2E133E33E6

The Anti-Obesity Therapeutics Market was valued at USD 11.69 billion in 2025 and is projected to grow to USD 12.67 billion in 2026, with a CAGR of 8.87%, reaching USD 21.21 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 11.69 billion
Estimated Year [2026] USD 12.67 billion
Forecast Year [2032] USD 21.21 billion
CAGR (%) 8.87%

An authoritative orientation to the evolving anti-obesity therapeutics ecosystem that frames scientific advances, clinical practice, and commercial imperatives for decision-makers

The global effort to confront obesity has accelerated into a high-stakes, multidisciplinary arena where biomedical innovation, clinical practice, payer decisions, and patient expectations converge. Recent years have seen the emergence of novel pharmacotherapies, evolving surgical and endoscopic interventions, and an intensified focus on long-term outcomes and safety. Against this backdrop, stakeholders must navigate a complex regulatory environment, shifting reimbursement signals, and growing public attention to access and equity.

This executive summary synthesizes the most consequential developments shaping the anti-obesity therapeutics landscape today. It is written for executives, clinical leaders, policy advisors, and investors who require a concise, evidence-based orientation to the opportunities and operational challenges ahead. In the sections that follow, we summarize transformative scientific shifts, assess the implications of new tariff policies introduced in the United States in 2025, unpack granular segmentation insights, distill regional dynamics, profile competitive positioning, and propose concrete actions to accelerate patient access while protecting commercial value. Taken together, these insights aim to enable informed decisions that balance innovation, safety, and sustainable market execution.

A clear synthesis of the scientific breakthroughs, delivery innovations, and care pathway realignments that are reshaping therapeutic possibilities and commercial strategies

The landscape for anti-obesity therapeutics has shifted from incremental improvement to transformational change as a result of converging scientific, regulatory, and commercial forces. Breakthroughs in peptide and incretin biology have redefined therapeutic targets and clinical expectations, prompting renewed investment in both pharmacologic and device-based interventions. At the same time, real-world evidence and longer-duration clinical programs have elevated safety signaling and health-economic considerations, causing manufacturers and payers to align earlier on outcomes that matter to patients and systems.

Concurrently, delivery innovations and route-of-administration strategies have altered patient adherence paradigms and opened new channels for engagement. This has driven the emergence of integrated care pathways that combine medication, device, digital support, and behavioral interventions for sustained weight management. As a result, clinical development programs increasingly prioritize durability of effect, tolerability, and comparative effectiveness, while commercialization strategies emphasize differentiated value propositions, patient support services, and partnerships with specialty and primary care providers. These transformative shifts require stakeholders to adopt agile evidence-generation plans and holistic go-to-market models that span product, payer, and provider ecosystems.

An analytical account of how recent tariff policies have compelled supply chain resilience, sourcing shifts, and commercial coordination across anti-obesity product lifecycles

The tariff measures enacted in the United States in 2025 introduced new considerations for manufacturers, distributors, and providers involved in the supply chain for anti-obesity therapeutics. Although tariff policy is only one factor among many, it has immediate operational implications for sourcing, pricing strategies, and distribution logistics. Organizations exposed to tariff-affected inputs have had to reassess supplier contracts, ramp up domestic sourcing where feasible, and model the downstream effects on trade flows and contractual obligations.

Beyond procurement, the tariffs have prompted more active cross-functional coordination within companies, compelling commercial, regulatory, and supply teams to collaborate on mitigation strategies that preserve patient access while protecting margins. For some manufacturers, the policy environment accelerated plans to localize certain production activities or to reconfigure product packaging and distribution hubs to minimize tariff exposure. For payers and providers, the tariffs have emphasized the importance of transparent pricing conversations and proactive engagement on formulary placement and prior authorization processes. In short, the cumulative impact of the 2025 tariffs has been to highlight supply chain resilience and strategic sourcing as central components of commercial planning for anti-obesity therapeutics.

Strategic segmentation-driven insights that reveal therapeutic, delivery, formulation, and channel distinctions guiding development priorities and commercialization choices

Segmentation insights provide the granular perspective necessary to align clinical development with commercial execution and patient needs. Based on Treatment Type, the market is studied across Medications and Treatments, with Medications further examined across Bupropion-Naltrexone, Liraglutide, Orlistat, Phentermine-Topiramate, Semaglutide, and Tilzepatide, while Treatments are evaluated across Adjustable Gastric Banding, Endoscopic Sleeve Gastroplasty, and Gastric Bypass Surgery. This dual axis highlights how pharmaceutical innovation and procedural interventions coexist and compete within care pathways, and how decision-making differs between chronic pharmacotherapy and one-time or episodic procedural interventions.

Based on Drug Type, the market is studied across Over-The-Counter Drugs and Prescription Drugs, reflecting distinct regulatory regimes, patient self-care behaviors, and payer interactions that influence access and adherence. Based on Route Of Administration, the market is studied across Oral Administration and Parenteral Administration, with Oral Administration further examined across Capsules and Tablets, and Parenteral Administration further examined across Intravenous and Subcutaneous, underscoring how delivery mode drives clinical adoption, patient preference, and health-system readiness. Finally, based on Drug Formulation, the market is studied across Liquid Dosage Forms, Semi-Solid Dosage Forms, and Solid Dosage Forms, while distribution considerations are captured based on Distribution Channel where the market is studied across Hospitals & Clinics Pharmacies, Online Pharmacies, and Retail Pharmacies. Together, these segmentation lenses reveal where innovation clusters, where reimbursement friction is most likely to occur, and where targeted evidence generation and patient support investments can produce the greatest commercial leverage.

A nuanced regional assessment of regulatory, payer, and clinical dynamics that dictates differentiated go-to-market tactics across major global territories

Geography continues to shape regulatory pathways, payer behavior, clinical practice norms, and patient access in ways that materially influence product strategy. In the Americas, policy debates around coverage and affordability intersect with growing clinician familiarity with novel agents, creating both access opportunities and pressure for robust outcomes data. Manufacturers operating in this region must balance aggressive evidence-generation with proactive payer engagement and patient support capabilities to ensure sustained uptake.

In Europe, Middle East & Africa, heterogeneity across national systems requires differentiated market entry and pricing strategies, with some jurisdictions prioritizing cost-effectiveness evidence and others focusing on therapeutic value in specific patient cohorts. This region often demands more localized health-economic models and targeted post-launch real-world studies. In Asia-Pacific, rapid adoption of new therapies in select urban centers is counterbalanced by variable reimbursement frameworks and supply chain complexity; the region therefore rewards flexible distribution models and partnerships with established regional healthcare providers. Across all regions, cross-border collaboration on regulatory science and harmonized approaches to safety monitoring can accelerate appropriate access while protecting patient welfare.

A comprehensive competitive synthesis revealing how pharmaceutical, biotechnology, and device firms differentiate through evidence, partnerships, and integrated care solutions

Competitive dynamics in anti-obesity therapeutics reflect a mix of large diversified pharmaceutical firms, specialized biotechs, and device-focused companies, each pursuing strategies that combine clinical differentiation with scalable commercialization. Established biopharmaceutical companies leverage development expertise and global distribution networks to pursue broad indications and lifecycle management, while biotechs frequently focus on novel mechanisms of action, targeted patient segments, and partnership-driven commercialization.

Device and procedural players emphasize outcomes that matter in surgical and endoscopic interventions, investing in training, center-of-excellence models, and integration with ambulatory care pathways. Across all company types, strategic priorities include demonstrating comparative effectiveness versus existing standards, developing patient support ecosystems that improve adherence and persistence, and building payer evidence that links clinical outcomes to economic benefit. As competition intensifies, alliances between drug and device innovators, digital health providers, and specialty care networks are likely to increase, reflecting a marketplace where integrated solutions that span prevention, treatment, and long-term management create durable competitive advantages.

Practical and prioritized actions for executives to align evidence generation, patient support, supply resilience, and partnerships for durable commercial success

To convert scientific promise into sustainable impact, industry leaders should prioritize several actionable moves. First, align clinical development with payer evidence needs by embedding health-economic endpoints and pragmatic outcomes into pivotal and post-marketing studies; this will shorten time-to-coverage discussions and reduce access friction. Second, invest in patient-centric support models that address initiation, adherence, and tolerability management, recognizing that real-world persistence is a critical driver of long-term therapeutic value.

Third, strengthen supply chain resilience through diversified sourcing and regional manufacturing where appropriate, thereby mitigating tariff exposure and ensuring consistent product availability. Fourth, pursue partnerships that integrate pharmacologic treatments with device-based interventions, digital therapeutics, and behavioral programs to create differentiated value propositions for clinicians and payers. Finally, engage proactively with regulators and payers to design adaptive evidence-generation pathways that can incorporate real-world data and conditional coverage arrangements. By operationalizing these recommendations, organizations can accelerate responsible access while safeguarding commercial viability.

A transparent mixed-methods research approach combining stakeholder interviews, clinical literature review, regulatory analysis, and scenario-based synthesis to underpin conclusions

This research draws on a mixed-methods approach that integrates primary and secondary sources to deliver a rigorous, multi-dimensional perspective. Primary research includes structured interviews with stakeholders across clinical, payer, industry, and distribution channels, supplemented by detailed reviews of regulatory guidance and publicly available clinical trial registries. Secondary analysis encompassed peer-reviewed clinical literature, safety updates, and published health-technology assessment decisions to ensure the evidence base reflects both efficacy and real-world performance.

Analytical methods combined thematic synthesis with scenario analysis to explore strategic sensitivities such as reimbursement shifts, supply chain interruptions, and evolving standard-of-care practices. Where appropriate, triangulation across data sources was used to validate findings and highlight areas of consensus or divergence among stakeholders. The methodology emphasizes transparency in source attribution and methodological choices so that readers can assess the applicability of insights to their specific operating contexts.

A concise synthesis of strategic imperatives emphasizing evidence, patient access, and integrated care models as decisive factors for long-term impact

In conclusion, the anti-obesity therapeutics landscape is entering a maturation phase defined by meaningful scientific progress, heightened expectations for safety and long-term outcomes, and complex commercial dynamics that include supply chain and policy considerations. Success in this environment will depend on the ability of organizations to generate compelling comparative evidence, deploy patient-centric support programs, and adapt operational models to mitigate tariff and sourcing risks. At the same time, opportunities abound for those who can integrate pharmacologic innovation with procedural options and digital supports to deliver comprehensive, sustainable care pathways.

Going forward, stakeholders who combine rigorous clinical development, agile commercial execution, and proactive payer engagement will be best positioned to translate breakthroughs into widespread, equitable patient access. The strategic choices made now-about evidence strategy, partnerships, and organizational capabilities-will determine which therapies achieve lasting clinical and commercial impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anti-Obesity Therapeutics Market, by Treatment Type

  • 8.1. Medications
    • 8.1.1. Bupropion-Naltrexone
    • 8.1.2. Liraglutide
    • 8.1.3. Orlistat
    • 8.1.4. Phentermine-Topiramate
    • 8.1.5. Semaglutide
    • 8.1.6. Tilzepatide
  • 8.2. Treatments
    • 8.2.1. Adjustable Gastric Banding
    • 8.2.2. Endoscopic Sleeve Gastroplasty
    • 8.2.3. Gastric Bypass Surgery

9. Anti-Obesity Therapeutics Market, by Drug Type

  • 9.1. Over-The-Counter Drugs
  • 9.2. Prescription Drugs

10. Anti-Obesity Therapeutics Market, by Route Of Administration

  • 10.1. Oral Administration
    • 10.1.1. Capsules
    • 10.1.2. Tablets
  • 10.2. Parenteral Administration
    • 10.2.1. Intravenous
    • 10.2.2. Subcutaneous

11. Anti-Obesity Therapeutics Market, by Drug Formulation

  • 11.1. Liquid Dosage Forms
  • 11.2. Semi-Solid Dosage Forms
  • 11.3. Solid Dosage Forms

12. Anti-Obesity Therapeutics Market, by Distribution Channel

  • 12.1. Hospitals & Clinics Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Anti-Obesity Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Anti-Obesity Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Anti-Obesity Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Anti-Obesity Therapeutics Market

17. China Anti-Obesity Therapeutics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Alizyme PLC
  • 18.6. Amgen Inc.
  • 18.7. Arena Pharmaceuticals Inc.
  • 18.8. Boehringer Ingelheim International GmbH
  • 18.9. Bristol-Myers Squibb Company
  • 18.10. Currax Pharmaceuticals LLC
  • 18.11. Eisai Co. Ltd.
  • 18.12. Eli Lilly and Company
  • 18.13. F. Hoffmann-La Roche Ltd
  • 18.14. FlaxoSithKline plc.
  • 18.15. GlaxoSmithKline PLC
  • 18.16. Johnson & Johnson Services Inc.
  • 18.17. Merck & Co. Inc.
  • 18.18. Nalpropion Pharmaceuticals Inc.
  • 18.19. Norgine B.V.
  • 18.20. Novartis AG
  • 18.21. Novo Nordisk A/S
  • 18.22. Orexigen Therapeutics Inc.
  • 18.23. Pfizer Inc.
  • 18.24. Rhythm Pharmaceuticals, Inc.
  • 18.25. Sanofi S.A.
  • 18.26. SHIONOGI & Co., Ltd.
  • 18.27. Takeda Pharmaceutical Company Limited
  • 18.28. Vivus Inc.
  • 18.29. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY BUPROPION-NALTREXONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY BUPROPION-NALTREXONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY BUPROPION-NALTREXONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIRAGLUTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIRAGLUTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORLISTAT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORLISTAT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORLISTAT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PHENTERMINE-TOPIRAMATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PHENTERMINE-TOPIRAMATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PHENTERMINE-TOPIRAMATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMAGLUTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMAGLUTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TILZEPATIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TILZEPATIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TILZEPATIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ADJUSTABLE GASTRIC BANDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ADJUSTABLE GASTRIC BANDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ADJUSTABLE GASTRIC BANDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GASTRIC BYPASS SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GASTRIC BYPASS SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GASTRIC BYPASS SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIQUID DOSAGE FORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIQUID DOSAGE FORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIQUID DOSAGE FORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SOLID DOSAGE FORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SOLID DOSAGE FORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SOLID DOSAGE FORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 181. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 182. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 187. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 211. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 212. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 214. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 216. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 217. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 221. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 222. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 225. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 226. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 227. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)